Submental Fat
14
0
0
14
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
21%
3 trials in Phase 3/4
43%
6 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (14)
Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat
A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
Efficacy and Safety of RZL-012 on Submental Fat Reduction
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat